BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment

Joint Bone Spine. 2013 Jul;80(4):433-4. doi: 10.1016/j.jbspin.2012.10.004. Epub 2012 Nov 16.
No abstract available

Keywords: Ankylosing spondylitis; Anti-tumor necrosis factor treatment; BAFF; BLyS.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antirheumatic Agents / therapeutic use
  • B-Cell Activating Factor / blood*
  • Case-Control Studies
  • Humans
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood*
  • Spondylitis, Ankylosing / drug therapy*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • B-Cell Activating Factor
  • TNFSF13B protein, human
  • Tumor Necrosis Factor-alpha
  • Adalimumab